Medscape
NEW YORK — In a three-way debate on whether to prioritize chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies (BsAbs), or one of the novel oral targeted therapies for relapsed/refractory follicular lymphoma (R/R FL), no expert conceded. Acknowledging that hers was the weakest position, even the specialist who defended novel targeted therapies mounted a staunch …
Read More
Lymphoma Debate: CAR T Not a Clear Winner
Jeanice Schildgen
18:21
NEW YORK — In a three-way debate on whether to prioritize chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies (BsAbs), or one of the novel oral targeted therapies for relapsed/refractory follicular lymphoma (R/R FL), no expert conceded. Acknowledging that hers was the weakest position, even the specialist who defended novel targeted therapies mounted a staunch
